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Abstract 19 
ETHNOPHARMACOLOGICAL RELEVANCE:  20 
Osteoporosis is a chronic epidemic which can lead to enhanced bone fragility and 21 
consequent an increase in fracture risk. Traditional Chinese medicine (TCM) formulas have a 22 
long history of use in the prevention and treatment of osteoporosis. Antiosteoporotic TCM 23 
formulas have conspicuous advantage over single drugs. Systematic data mining of the 24 
existing antiosteoporotic TCM formulas database can certainly help the drug discovery 25 
  2 
processes and help the identification of safe candidates with synergistic formulations. In this 1 
review, the authors summarize the clinical use and animal experiments of TCM formulas and 2 
their mechanism of action, and discuss the potential antiosteoporotic activity and the active 3 
constituents of commonly used herbs in TCM formulas for the therapy of osteoporosis. 4 
MATERIALS AND METHODS:  5 
The literature was searched from Medline, Pubmed, ScienceDirect, Spring Link, Web of 6 
Science, CNKI and VIP database from 1989 to 2015, and also collected from Chinese 7 
traditional books and Chinese Pharmacopoeia with key words such as osteoporosis, osteoblast, 8 
osteoclast, traditional Chinese medicine formulas to identify studies on the antiosteoporotic 9 
effects of TCM formulas, herbs and chemical constituents, and also their possible mechanisms. 10 
RESULTS:  11 
Thirty-three TCM formulas were commonly used to treat osteoporosis, and showed 12 
significant antiosteoporotic effects in human and animal. The herb medicines and their 13 
chemical constituents in TCM formulas were summarized, the pharmacological effects and 14 
chemical constituents of commonly used herbs in TCM formulas were described in detail. The 15 
action mechanisms of TCM formulas and their chemical constituents were described. Finally, 16 
the implication for the discovery of antiosteoporotic leads and combinatory ingredients from 17 
TCM formulas were prospectively discussed. 18 
CONCLUSIONS:  19 
Clinical practice and animal experiments indicate that TCM formulas provide a definite 20 
therapeutic effect on osteoporosis. The active constituents in TCM formulas are diverse in 21 
chemical structure, and include flavonoids, lignans, saponins and iridoid glycosides. 22 
Antiosteoporotic mechanism of TCM formulas and herbs involves multi regulatory pathways, 23 
such as Wnt/β-catenin, BMP/Smad, MAPK pathway and RANKL/OPG system. 24 
Phytochemicals from TCM formulas and their compositional herb medicines offer great 25 
potential for the development of novel antiosteoporotic drugs. The active ingredients in TCM 26 
formulas can be developed in combination as potent drugs, which may exhibit better 27 
antiosteoporotic effects compared to the individual compound. 28 
  3 
Chemical compounds studied in this article 1 
Aucubin (PubChem CID: 91458); Ecdysterone (PubChem CID: 271605); Catalpol (PubChem 2 
CID: 91520); Ferulic acid (PubChem CID: 445858); Sweroside (PubChem CID: 161036); 3 
Formononetin (PubChem CID: 5280378); Cinnamaldehyde (PubChem CID: 637511); 4 
AsperosaponinⅥ (PubChem CID: 71307450); Emodin (PubChem CID: 3220); Kaempferol 5 
(PubChem CID: 5280863) 6 
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1. Introduction 18 
Osteoporosis, a chronic epidemic, is characterized by low bone mass and 19 
microarchictectural deterioration of bone tissues, leading to enhanced bone fragility and 20 
consequent increase in fracture risk (Appelman-Dijkstra and Papapoulos, 2015). Osteoporosis 21 
is a growing problem worldwide, with the greatest burden resulting from fractures. It is 22 
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estimated that more than 200 million people worldwide suffer from osteoporosis.(Lewiecki, 1 
2011). These numbers are expected to steadily increase over time, with osteoporosis affecting 2 
an estimated 14 million people with over 47 million cases of low bone mass by the year 2020 3 
(Ford et al., 2011). Treatment of osteoporosis consists of pharmacotherapy and lifestyle 4 
measures, including dietary changes, mineral supplementation, and exercise programs. 5 
Currently, the most commonly used agents for the treatment of osteoporosis include 6 
raloxifene; bisphosphonates alendronate, ibandronate, risedronate and zoledronic acid; agents 7 
derived from parathyroid hormone (PTH); denosumab and strontium ranelate, and also 8 
hormone replacement. However, due to adverse effects of the drugs, the uses of these 9 
medications on a long term basis are limited.  10 
Traditional Chinese medicine (TCM) has been used in China and other Asian countries 11 
for thousands of years (Jin et al., 2013), either as mono-therapy or in combination with 12 
standard Western medical treatment, to manage the entire spectrum of medical disorders. 13 
TCM formulas are often composed of more than one herb, and the main principle underlying 14 
the use of herbal formulas is that complex interactions between herbs produce synergistic 15 
effects that can improve therapeutic efficacy, or reduce possible side-effects of individual 16 
herbs (Gao et al., 2013). In addition, TCM is rich in natural compounds and can be considered 17 
as a natural chemical library producing synergistic effects, which has been justified by the 18 
revealing function and synergistic mechanism of principle active ingredients, such as Fu Fang 19 
Qing Dai Pian. It also presents more diversity in chemical structure and bioactivity, and less 20 
toxicity. Therefore, TCM represents an attractive source of new active compounds in drug 21 
discovery, for example, derivatives of indirubin, a compound isolated from a TCM formulas 22 
Dang Gui Long Hui Wan displays antileukemic properties (Kim et al., 2013b). Our previous 23 
review has summarized the commonly used individual herbs and compounds used in the 24 
treatment of osteoporosis. In this review, we highlight the research on TCM formulas for 25 
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osteoporosis from clinical use to their mechanism of action; this may be helpful in the 1 
application of TCM formulas in the treatment of osteoporosis and the discovery of 2 
antiosteoporotic lead compounds either on their own or in combination with other herbs. 3 
2. Methods 4 
The literature were searched from Medline, Pubmed, ScienceDirect, Spring Link, Web of 5 
Science, CNKI and VIP database from 1989 to 2015, and also collected from Chinese 6 
traditional books and Chinese Pharmacopoeia to identify studies on the antiosteoporotic effects 7 
of TCM formulas, herbs and chemical constituents, and also their possible mechanisms. The 8 
following keywords were used for the search: osteoporosis, osteoblast, osteoclast, traditional 9 
Chinese medicine formulas. All of these keywords were searched for each plant and its 10 
constituents. All published studies in English or Chinese language were included in the review. 11 
The literature search was conducted by both authors independently, with no inconsistencies 12 
between the two authors. The review included the following steps: (1) the TCM formulas for 13 
the treatment of osteoporosis in human and animal were reviewed using the available literature. 14 
(2) The herb medicine and their chemical constituents in TCM formulas were summarized. (3) 15 
The possible mechanism of action of TCM formulas and their chemical constituents were 16 
reviewed.  17 
3. Clinical efficacy of TCM therapy for osteoporosis 18 
Osteoporosis are caused by multiple factors, such as estrogen deficiency, aging, chemical 19 
agents and decreased mechanical loading, and afflicted patients should be treated with different 20 
TCM formulas according to different syndromes. Thirty-three TCM formulas have been 21 
reported in ethnopharmacological studies for their potential benefits in osteoporosis treatment 22 
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including 5 classic formulas, 23 empirical formulas, and 5 Chinese patent medicines. Multiple 1 
references were consulted for detailed information on research status of major TCM formulas 2 
which are discussed below.  3 
The classic formulas which have been recorded in ancient medicine books have definitive 4 
efficacy, and often are standardized in preparation using traditional technique according to 5 
traditional Chinese medicine theory, and also commercially available. The formulas, such as 6 
Qing E Wan, Er Zhi Wan (EZW), Zuo Gui Wan (ZGW), You Gui Wan (YGW) and Liu Wei Di 7 
Huang Wan (LW) are used to treat osteoporosis through reinforcing the kidney, and clinicians 8 
can usually remove or add one or more herbs, and adjust their dosage in the prescription 9 
according to differentiation of the patient's physical condition. The ingredients, recorded 10 
literature, efficacy and indication, usage and dosage of classic formulas for the treatment of 11 
osteoporosis are shown in Table 1. Examples are as follows. Treatment of postmenopausal 12 
osteoporosis of 48 women with Qing E Wan for 24 weeks significantly increased bone mineral 13 
density (BMD), activity of bone alkaline phosphates and osteocalcin (OCN); decreased the 14 
levels of serum matrix metalloproteinase-2, bone cross-linked C-telopeptides of typeⅠ15 
collagen, urine bone cross-linked N-telopeptides of typeⅠcollagen compared with placebo 16 
treatment (Zhao and Shen, 2012),indicating that Qing E Wan can increase osteoblastic bone 17 
formation, and inhibit osteoclastic bone resorption, and then reduce bone lose in 18 
postmenopausal women. However, this investigation lacks the information of Qing E Wan in 19 
relieving clinical syndrome, such as pain in back and loin. The effect of EZW on climacteric 20 
osteoporosis has been observed by the administration of EZW to 40 patients for 6 months and 21 
it was found that this formula significantly increased BMD and level of estradiol in serum 22 
compared to patients treated with calcium preparation (Yu, 2009). Due to lack the biochemical 23 
parameters of bone metabolism in serum, it is difficult to evaluate the regulatory effects of 24 
EZW on bone metabolism. The increase of the levels of estradiol may lead to adverse effects 25 
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on uterus and mammary gland. The adverse effects related with estrogen-like activity should 1 
be further investigated. The treatment of 30 patients with type 2 diabetic osteoporosis with 2 
ZGW significantly increased BMD, and decreased levels of OCN, parathyroid hormone and 3 
alkaline phosphatase (ALP) in serum compared with control group (Wang et al., 2014b).ZGW 4 
also showed more potential effects in relieving bone pain, therefore indicating significant 5 
advantage than calcium preparation. These findings exhibited that ZGW can regulate bone 6 
formation, but the effects on bone resorption are not clear in patients with type 2 diabetic 7 
osteoporosis. Administration of YGW in 30 patients with kidney-deficiency osteoporosis for 3 8 
months significantly increased BMD and activity of ALP, and decreased urinary calcium level, 9 
indicating that YGW can be used to treat osteoporosis (Liang et al., 2011). In this research, the 10 
ages of patients were range from 65 to 83 years old; the indications of YGW should be senile 11 
osteoporosis. The therapeutic effects of YGW on postmenopausal osteoporosis need to be 12 
further investigated. Treatment with LW in 30 primary osteoporotic patients caused by 13 
kidney-yin deficiency for 12 months achieved better effectiveness in BMD of lumber, ratio of 14 
urinary Ca/Cr and the total effective rate than that of calcium carbonate treatment (Zhang and 15 
Li, 2011). The ages of patients in this study were range from 50 to 80 years old, the senile 16 
osteoporosis and postmenopausal osteoporosis are not discriminated during the process of 17 
results analysis. 18 
Empirical formulas, which are derived from a summary of clinician’s experience in 19 
long-term medical practice, has definite efficacy leading to a standard formula composition. 20 
These formulas are also standardized in preparation by investigator, but are not permitted to 21 
sell in market, and only used for treatment disease in the institute of investigator. The 22 
commonly used empirical formulas for the treatment of osteoporosis include Gu Song Kang, Er 23 
Xian Decoction (EXD), Fu Fang Lu Rong Jian Gu Jiao Nang (LRJG) etc. The empirical 24 
formulas for the treatment of osteoporosis are shown in Table 2. For example, Gu Song Kang 25 
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treatment for 50 postmenopausal osteoporotic patients for 90 days showed better therapeutic 1 
effects than that with calcium lactate in increasing BMD and improving the patients conditions 2 
in osteoporotic patients (Wang et al., 2003) . In the formula of Gu Song Kang, Epimedium 3 
brevicornu Maxim and Cullen corylifolium (Linnaeus) Medikus and Angelica sinensis (Oliv.) 4 
Diels has estrogen-like activity, maybe increases the estrodiol level in serum and produces 5 
unwanted effects on patients. However, investigator did not concern this problem. Treatment 6 
with EXD in 35 postmenopausal osteoporotic patients for 12 weeks significantly elevated BMD 7 
and levels of ALP, estrodiol, OCN and calcitonin in serum, relieve the pain syndrome, and 8 
showed more potential efficacy than treatment with salmon calcitonin alone (Zhu and Gu, 9 
2012). The results of biochemical marker in serum exhibited that EXD enhanced BMD 10 
through increasing bone formation. But the effects of EXD on bone resorption parameters in 11 
serum need to be determined so as to evaluate the regulatory activity on bone resorption. To 12 
study the effects of LRJG on primary osteoporosis, 401 patients were selected and randomly 13 
divided into LRJG treatment group (n=301) and Gu Shu Kang (GSK) treatment group (n=100), 14 
and treatment with LRJG for 6 months significantly improved BMD, and the effective rate of 15 
LRJG treatment was significantly higher than observed in the GSK group (Li et al., 2010). 16 
LRJG did not produce any effects on calcium, phosphorus and ALP activity, this maybe is 17 
related with no discrimination from postmenopausal and senile osteoporosis, and other 18 
biochemical markers were not measured in serum. Therefore, this investigation did not clarify 19 
the regulatory mechanism on bone metabolism. To objectively evaluate the therapeutic effect 20 
and safety of Yi Shen Zhuang Gu He Ji (YSZG) in primary osteoporosis, 96 patients were 21 
treated with YSZG, 32 patients were given Ostrea gigas Thunberg and 32 patients were given 22 
placebo for 6 months. The results indicated that treatment with YSZG produce more significant 23 
therapeutic effects than that of Ostrea gigas Thunberg as evidenced by BMD, serum BGP and 24 
PYD (Wang et al., 2005), indicating that YSZG not only regulate bone formation, but also 25 
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modulate bone resorption. The change of estrogen levels should be determined so as to predict 1 
the action mechanism and safety of YSZG. 2 
Chinese patent medicines, which are approved by the State Food and Drug Administration 3 
of China, are standardized in preparation by pharmaceutical company, and are commercially 4 
available in market. They are often used alone or in combination with chemical drugs to treat 5 
various diseases. Chinese patent medicines for the treatment of osteoporosis include Xian Ling 6 
Gu Bao Jiao Nang (XLGB), Gu Shu Kang Jiao Nang (GSK), Gu Song Bao Jiao Nang, Hu Gu 7 
Jiao Nang and Jin Tian Ge Jiao Nang (JTG). These TCM formulas have the characteristic of 8 
fixed composition and dosage and no herbs can be either added or removed from the formulas. 9 
The Chinese patent medicines for the treatment of osteoporosis are shown in Table 3. For 10 
example, 180 healthy postmenopausal women more than 60 years old with BMD T-score ≤ 11 
−2.0 (lumbar spine or femoral neck) were randomly divided into three groups, and given 12 
XLGB at dose of 3 g/day (n=61), XLGB at dose of 6 g/day (n=58) or placebo (n=61), 13 
respectively. Treatment with XLGB for 12 months significantly increased lumbar spine BMD, 14 
declined bone turnover marker levels and did not produce any adverse effects (Zhu et al., 15 
2012). This was the first multicenter, double-blind, placebo controlled clinical trial to provide 16 
evidence showing the safety and efficacy of the oral “bone strengthening” herbal XLGB with 17 
phytoestrogenic compounds for the treatment of osteoporosis in postmenopausal women. 18 
However, estrogen-dependent tissues were not clinically examined. The future clinical studies 19 
shall be designed for safety of estrogen-dependent tissues. To evaluate the curative effects and 20 
advantages of combining Chinese and chemical medicine in treating senile osteoporosis, 66 21 
patients of senile osteoporosis were randomly divided into two groups, and treated with GSK 22 
(n=35), and simultaneously treated with salcatonin, ossotide for injection, calcium carbonate 23 
and Vitamin D3 for 6 months. GSK treatment significantly increased BMD and had a higher 24 
effective rate than that of the control group (Feng et al., 2013b), indicating that GSK 25 
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combination with chemical medicine enhanced BMD, and improve the clinical syndrome of 1 
senile osteoporosis. Due to lack of observation of GSK alone on senile osteoporosis, the 2 
therapeutic effectiveness of GSK need to be further investigated. To explore the effectiveness 3 
of dynamic hip screw (DHS) combined with JTG Jiao Nang in the treatment of osteoporotic 4 
femoral inter-trochanteric fractures, 44 cases were randomly treated with either DHS or DHS 5 
combined with JTG Jiao Nang for 6 months. The BMD of the proximal end of the femur of 6 
patients treated with combinational therapy was higher than that of treatment of DHS alone 7 
(Liao et al., 2011), indicating that JTG can decrease bone loss through increasing BMD and 8 
improving bone biomechanical property. However, this study did not determine the alteration 9 
of serum biochemical parameters related with bone metabolism. 10 
According to the guidelines for clinical evaluation of agents used in the prevention and 11 
treatment of postmenopausal osteoporosis approved by the Food and Drug Administration, the 12 
clinical observation for anti-osteoporotic drugs should determine BMD and the serum 13 
biochemical parameters, such as vitamin D, urine hydroxyproline, Ca etc, and in double-blind, 14 
placebo-controlled trail for 12 months in phase Ⅱ clinical study. Based on the characteristics of 15 
TCM formulas, Food and Drug Administration of China suggested that clinical observation of 16 
TCM drugs for reducing fracture incidence should last more than for 3 years, and that for 17 
relieving or alleviating the clinical symptoms should last for 6 months, while the indexes of 18 
effectiveness included bone mineral density and bone turnover markers. The clinical 19 
investigations showed that TCM formulas are effectiveness in preventing and treating 20 
osteoporosis, especially in alleviation of the pain symptoms. However, there are still many 21 
problems in clinical trials. For example, the most of reported clinical investigations are general 22 
clinical observations instead of application of RCT designed clinical studies. The method of 23 
randomization was often inappropriately described; the sample sizes are 50-100 patients, and 24 
are less than 200 in most of studies. Over half did not report and analysis side effects. The 25 
  12 
duration of clinical trials often last 3-6 months, did not reach to the requirements of 6 months or 1 
3 years. Most of these trials combined with other interventions, such as calcitonin, calcium 2 
preparation; the efficacy of TCM formulas on osteoporosis is not confirmed. Some clinical 3 
studies about primarily osteoporosis did not distinguish and assess the effects on 4 
postmenopausal and senile osteoporosis, respectively. The indexes of effectiveness focused on 5 
bone mineral density, and lack of biochemical parameters in serum and urine. Therefore, in 6 
clinical study researchers should adhere to the guidelines of FDA and SFDA of China to design 7 
experimental therapeutic efficacy parameters, observational period, sample size, and also 8 
including random and double-blinded control to improve and standardize clinical trials of TCM 9 
formulas for the treatment of osteoporosis. 10 
4. Antiosteoporotic activity of TCM formulas in several important animal models 11 
The animal models that have been established and used to understand the pathogenesis of 12 
osteoporosis and for the preclinical evaluation of drugs include castrated osteoporotic models, 13 
osteoporotic models caused by chemical drugs and disuse osteoporotic models. The 14 
antiosteoporotic effects of TCM formulas in animal experiments were summarized in Table 4. 15 
4.1 Castrated osteoporotic model 16 
The ovariectomized rat is the most common used animal model in the study of 17 
anti-osteoporotic medications. Ovariectomy (OVX) leads to a rapid bone loss up to 100 days. 18 
The mechanism of bone loss currently accepted for the estrogen-deficient rat is an imbalance in 19 
bone turnover, i.e., bone resorption exceeds bone formation. This model mimics 20 
postmenopausal cancellous bone loss when examined over relatively short periods of time 21 
(Sharma et al., 2012; Turner et al., 2013). However, observation periods of 12 months or longer 22 
have revealed higher values of bone mineral content (BMC), bone area and body weight in 23 
ovariectomized rats. Furthermore, the lack of the haversian system in cortical bone, the absence 24 
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of impaired osteoblast function during the late stages of estrogen deficiency and the absence of 1 
multicellular unitbased remodeling in young rats limits the usefulness of this model (Egermann 2 
et al., 2005). Qing E Wan treatments of ovariectomized rats restored the estrus cycle and 3 
demonstrated significantly estrogenic activity, as indicated by reversal of uterine atrophy, 4 
reduction in rectal temperature (Xu et al., 2010). Administration of EZW could significantly 5 
prevent ovariectomy-induced bone loss, biomechanical reduction, deterioration of trabecular 6 
microarchitecture and the body weight without affecting the weight of the uterus, and increased 7 
Ca and P levels in serum, decreased level of bone turnover markers and Ca and P levels in urine 8 
in ovariectomized rats without hyperplastic effect on uterus (Cheng et al., 2011). ZGW 9 
improved bone trabecular and decreased OCN and tartrate-resistant acid phosphate (TRAP) in 10 
ovariectomized osteoporotic rats (Lv et al., 2010). EXD could significantly improved BMD, the 11 
maximum bending stress, and the loading force of the 5th lumbar vertebra, increase serum ALP 12 
and superoxide dismutase (SOD) activity, and lower the serum levels of TRAP and 13 
malondialdehyde (MDA) in ovariectomized rats (Liu et al., 2014a). XLGB treatment increased 14 
bone density and estrogen level (Wang et al., 2010). GSK had obviously ameliorating effects on 15 
the bone loss in OVX rats. Treatment with LW for 26 weeks could significantly decrease the 16 
level of ALP and OCN in serum, increase the BMD of femurs, and improve the biomechanical 17 
capability of vertebral body in maximum loading and elastic modulus. Ba Wei Di Huang Wan 18 
combined with antiresorptive agent, alendronate (ALN) increased trabecular bone volume and 19 
BMD, improved the microstructure of the bone in both proximal tibia and vertebra with no 20 
marked effects on bone formation (Chen et al., 2012). Treatment of mice with Si Wu Tang 21 
(SWT) extract increased bone formation, and prevented bone loss induced by ovariectomy in 22 
vivo (Wu et al., 2013). Dang Gui Bu Xue Tang (DBT) combined with Epimedii Folium was 23 
able to attenuate osteoporosis by elevating the BMD levels of total body, and arrest the bone 24 
trabeculae degradation, decreased serum levels of MDA and increased endogenous SOD 25 
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activity (Xie et al., 2012). 1 
4.2 Osteoporotic model induced by chemical drugs 2 
Glucocoroticoids reduce bone density by diminishing intestinal calcium absorption, 3 
increasing renal clearance of calcium, and sex steroid deficiency. Furthermore, previous studies 4 
showed that glucocoroticoids exert pro-survival effect on osteoclasts, inbihit recruitment and 5 
activity of osteoblasts, and induce apoptosis of osteoblasts and osteocytes, leading to reduction 6 
in bone formation and increased bone resorption (Bocker et al., 2014; Piemontese et al., 2015). 7 
Therefore, glucocoroticoids-induced model is used to investigate the mechanism that how the 8 
drugs treat osteoporosis. It is known that glucocorticoid-induced osteoporosis differs from 9 
postmenopausal or senile osteoporosis. Histomorphometric parameters and biochemical 10 
markers of bone metabolism only indicate the decrease in bone formation and minimal changes 11 
in bone resorption. In order to study the aspects of bone fragility and implant fixation, the 12 
animal models using glucocorticoid induced osteoporosis simulate the human situation more 13 
closely than other models do (Allen et al., 2002; Egermann et al., 2005). The decrease of BMD 14 
and biomechanical competence is more pronounced when steroid medication is given than it is 15 
in the case of ovariectomy alone. However, long-term steroid treatment has been shown to have 16 
adverse effects, especially for the immune system, and ethical considerations need to be taken 17 
into account when using these models (Feng et al., 2013a). ZGW significantly increased 18 
trabecular bone volume (TBV%), trabecular formation surface (TFS%), the level of OCN, 19 
insulin-like growth factors (IGF) -1 and estrogen, and decreased content of PTH in serum in 20 
osteoporotic rats induced by dexamethasone (Li et al., 2011; Liu et al., 2011). Hu Gu Jiao Nang 21 
treatment significantly increased the BMDs of the femur and lumbar vertebra 5, and trabecular 22 
number (Tb.N), trabecular bone area (Tb.Ar), mineralizing surface/bone surface (MS/BS), 23 
mineral apposition rate (MAR), and bone formation rates (BFRs), and decreased trabecular 24 
separation (Tb. Sp) and eroded surface (ES/BS) in osteoporotic rats induced with 25 
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dexamethasone (Wang et al., 2012b).  1 
Retinoic acids (RA), major oxidative metabolites of vitamin A, play a regulatory role in 2 
many key processes, such as inhibition of cell proliferation, differentiation, apoptosis, shaping 3 
of the embryo, and organogenesis. With regard to osteoblastic cells, RA induces differentiation 4 
in primary cultures of both mouse and human osteoblasts, while increase the activity of 5 
osteoclasts (Broulik et al., 2013; Michalik and Wahli, 2007). Treatment with RA of 70 mg/kg 6 
body weight for 2 weeks will lead to bone loss and then osteoporosis. Due to the short time for 7 
forming models, osteoporotic model induced by RA is widely used to investigate the effects of 8 
drugs. GSK decreased bone resorption and increased bone formation by raising levels of 9 
estrogen and testosterone in blood of RA-induced osteoporotic rats (Cui et al., 2001). Jian Gu 10 
Ke Li significantly increased BMD of femur and tibia, and the level of chorionic thyrotropin in 11 
serum, and decreased the levels of PTH and tumor necrosis factor (TNF)-α in RA-induced 12 
osteoporotic rats (Lin et al., 2004). 13 
4.3 Disuse osteoporotic model 14 
The disuse osteoporosis refers to bone mass decrements under conditions of decreased 15 
mechanical loading, including decreased ground force reaction, muscular contraction, and 16 
microgravity-related bone loss in astronauts after space flights. The aetiology, pathophysiology, 17 
and resultant pathology of disuse osteoporosis differ from those of primary osteoporosis. The 18 
resulting bone loss from diminished weight bearing has been generated in animal models by 19 
nerve sectioning, tenotomy, casting of limbs, leg bandaging, internal joint fixation, external 20 
joint fixation, chair immobilization and spaceflight. Most studies reported a significant 21 
reduction of mineralization and histomorphometric parameters towards osteoporosis. The bone 22 
loss due to immobilization is apparent locally but not systemically, and therefore, is not 23 
appropriate to simulate human osteoporosis (Damrongrungruang et al., 2004; Jee and Ma, 1999; 24 
Jiang et al., 2006). Yi Shen Hu Gu decoction could increased the levels of OCN in serum, bone 25 
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mineral density, and decreased levels of ALP, TRAP, hydroxyproline (HYP) / creatinine (Cr), 1 
improved the bone biomechanical parameters (maximum loading and elastic modulus) and 2 
Tb.N in sciatic neurotomized disused osteoporotic rats (Ju et al., 2013). Wu Jia Bu Gu recipe 3 
increased bone density and femur maximum load and elastic load of rats after 3 weeks tail 4 
suspension, increased the activity of ALP, and levels of serum Ca and P, increased the 5 
deposition of external calcium, the production of collagen type I, increased BMD of femoral 6 
bone, maximum load and elastic load, TBV％, TFS％, anterior functional surface (AFS％) and 7 
MAR of lumbar (Fu et al., 2010). Bu Shen Zhuang Gu recipe increased BMD, the number of the 8 
trabecula, serum OCN, estrogen and P content, decreased serum calcium levels and resorption 9 
surface, improved the bone microstructure in weightlessness simulated rats by tail suspension 10 
for 4 weeks (Sun et al., 2007). 11 
In summary, the investigations of TCM formulas on osteoporotic model animals are 12 
mainly the search for new drugs or further proving the efficacy. However, these animal 13 
models are not totally consistent with human osteoporosis, and still need improvement. On 14 
the one hand, traditional Chinese medicine thinks that kidney governs bone, and primary 15 
osteoporosis is caused by deficiency of kidney and function disturbance of 16 
hypothalamic-pituitary-gonadal axis. However, osteoporotic animal models commonly used 17 
in the research of TCM formulas does not associate with kidney deficiency, and the 18 
pharmacological parameters also does not reflect the alteration in function of 19 
hypothalamic-pituitary-gonadal axis. On the other hand, the kidney deficiency in TCM 20 
includes two aspects of yin and yang, but there is no corresponding animal model to reflect 21 
the characteristic of kidney yin or yang deficiency. There is no discrimination between the 22 
reinforcing kidney yin and yang formulas in the treatment of osteoporosis. Therefore, 23 
osteoporotic animal model reflecting TCM yin and yang deficiency syndrome should be 24 
established, and used to investigate the antiosteoporotic effects of TCM formulas. 25 
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5. The herb medicines and their chemical constituents in TCM formulas for the therapy 1 
of osteoporosis 2 
A wealth of information indicates that TCM formulas for the therapy of osteoporosis 3 
contains a variety of herbal medicine, which can be divided into 3 categories based on their 4 
action in the formula：(1) replenishing kidney herb medicine, which commonly produces the 5 
marked effect; (2) strengthening spleen herb medicine; (3) activating blood circulation and 6 
dissipating blood stasis. There are more than 20 commonly used herbal medicines occurring in 7 
the antiosteoporotic formula. Their chemical constituents and pharmacological activities are 8 
summarized in Table 5. 9 
 Some important antiosteoporotic traditional Chinese medicine, including Cullen 10 
corylifolium (Linnaeus) Medikus (Fruit, Leguminosae), Epimedium plant (Leaf, 11 
Berberidaceae), Drynaria fortunei (Kunze ex Mett.) J.Sm.(Rhizome, Polypodiaceae) , Salvia 12 
miltiorrhiza Bunge (Root, Labiatae), Morinda officinalis How (Root, Rubiaceae) have been 13 
reviewed in our previous paper (Jia et al., 2012). Therefore, in this review we have focused on 14 
11 different antiosteoporotic herbal medicines, and their chemical constituents and 15 
antiosteoporotic activity are discussed below. 16 
5.1 Eucommia ulmoides Oliv. (Bark, Eucommiaceae) 17 
The bark of Eucommia ulmoides Oliv. has been shown to possess activity against 18 
hypertension, hyperglycemia, diabetes, obesity, osteoporosis, Alzheimer’s disease, aging, and 19 
sexual dysfunction, and contain various chemical constituents, including lignans, iridoids, 20 
phenolics, steroids, terpenoids, and ﬂavonoids. Lignans and iridoids are the two major 21 
constituents, such as liriodendrin, (p)-pinoresinol di-O-β-D-glucopyranoside, 22 
(p)-syringaresinol, aucubin, genipin, and geniposidic acid. Modern pharmacological and 23 
molecular biology studies have suggested that crude extracts and total glycosides of E. 24 
ulmoides may yield safe and mild anti-osteoporosis activities. E. ulmoides cortex extract 25 
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(EUCE) significantly inhibited OVX-induced decreases in biomechanical quality of the femur 1 
and improved bone microarchitecture, and dose dependently inhibited total bone mineral 2 
density decreases in the femur caused by OVX and decreased levels of the bone turnover 3 
markers OCN, ALP, deoxypyridinoline, and urinary Ca and P excretions (Zhang et al., 2009). 4 
EUCE significantly mitigated the decreases in bone volume/tissue volume, connect density, 5 
Tb.N, and trabecula thickness associated with OVX in rats and increased Tb.Sp, indicating that 6 
E. ulmoides exhibits preventive effects on estrogen deﬁciency-induced osteoporosis, and may 7 
be a potential alternative medicine for treatment of postmenopausal osteoporosis (Zhang et al., 8 
2009). EUCE could effectively prevent the bone loss induced by hind limb suspension, which 9 
was indicated by decreased levels of bone turnover markers as well as the changes in urinary 10 
calcium and phosphorus, and also enhanced the biomechanical strength of bone and prevented 11 
the deterioration of trabecular bone microarchitecture (Pan et al., 2014).  12 
The total lignans extracted from E. ulmoides signiﬁcantly prevented OVX-induced 13 
decrease in biomechanical quality of femur such as maximum stress and Young’s modulus, 14 
BMD decrease and microarchitecture deterioration. The total lignans increased cell 15 
proliferation, ALP activity and formation of bone calcified nodules, enhanced osteoprotegerin 16 
(OPG) expression and decreased RANKL expression of primary osteoblast from calvaria of 17 
neonatal rat, indicating that total lignans enhanced bone formation and inhibited 18 
osteoclastogenesis through OPG/RANKL system (Zhang et al., 2014). 19 
5-(Hydroxymethyl)-2-furaldehyde (5-HMF), isolated from E. ulmoides could increase the 20 
mRNA expression of ALP, pro-collagen type 1 α 1, OCN and OPN in RT-PCR analysis of 21 
osteoblast derived from bone mesenchymal stem cells, and decrease the mRNA expression of 22 
PPARγ, fatty acid binding protein 4, CCAAT/enhancer binding protein α of adipogenic cells 23 
from rat bone mesenchymal stem cells (BMSCs), enhanced the mineralized nodule formations 24 
of osteoblast, indicating that 5-HMF is a powerful inhibitor of adipogenesis and enhancer of 25 
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osteoblastogenesis (Tan et al., 2014). 1 
5.2 Achyranthes bidentata Bl. (Root, Amaranthaceae) 2 
The root of Achyranthes bidentata Bl. is recommended to reinforce the muscles and 3 
bones, improve the tone of the liver and kidneys, promote blood circulation and remove blood 4 
stasis, and is known to possess expectorant, anti-inﬂammatory, antipyretic, antirheumatic, and 5 
diuretic activities. The major constituents of the roots have been shown to be polysaccharides, 6 
saponins, ketosteroids, ﬂavonoids, sterols and alkaloids (He et al., 2014). The root of A. 7 
bidentata slowed down the body weight gain, enhanced the bone strength and prevented the 8 
deterioration of trabecular microarchitecture and loss of bone mass induced by the OVX 9 
through decreasing level of bone turnover markers, such as serum ALP, OCN and urinary 10 
deoxypyridinoline (DPD) (Zhang et al., 2012b). Two compounds, ecdysterone and daucosterol 11 
isolated from this plant markedly stimulated proliferation of osteoblast-like UMR106 cells (Li 12 
et al., 2001). Five new oleanolic acid glycosides could inhibit the formation of osteoclast-like 13 
multinucleated cells (OCLs) induced by 1alpha, 25(OH)2D3, and ﬂavonoid quercetin decreased 14 
osteoclastic differentiation in a co-culture system of osteoblast and bone marrow mononuclear 15 
cells. (Li et al., 2005a). The ketosteroids has been reported to prevent bone loss in 16 
ovariectomized animals (He et al., 2014). A. bidentata saponins are effective in preventing and 17 
treating retinoic acid-induced osteoporosis, and were found to induce proliferation and 18 
differentiation in bone marrow stromal cells (BMSCs) as evidenced by the osteoblastic 19 
proliferation and alkaline phosphatase activity. RT-PCR and Western-blot analysis showed 20 
that A. bidentata saponins increased mRNA levels of rat bone morphogenetic protein (BMP)-2, 21 
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runt-related transcription factor 2 and osterix, and increased the phosphorylation of ERK, 1 
indicating that A. bidentata saponins enhanced bone formation via activation of the ERK 2 
signaling pathway in osteoblast (He et al., 2014). 3 
5.3 Rehmannia glutinosa Libosch (Root, Scrophulariaceae) 4 
The root of Rehmannia glutinosa Libosch has been widely used to reduce fever, activate 5 
blood circulation, tonify the kidney, and has been used in the treatment of Yin deficiency 6 
syndrome in Eastern Asia for more than 2000 years. The steamed roots of R. glutinosa, possess 7 
anti-tumor, anti-stress, anti-thrombic, and hypoglycemic effects (Lim and Kim, 2013), and has 8 
been used as a haemostatic, cardio-tonic and diuretic agent. The major active components of the 9 
root of R. glutinosa are iridoid glycosides, such as catalpol and dihydrocatalpol, while other 10 
components are phenol glycoside, ionones, flavonoids, amino acids, inorganic ions and 11 
microelements (Zhang et al., 2008). The roots of R. glutinosa alleviated the decrease in the 12 
trabecular BMD, and increased the cortical bone thickness and trabeculation of the bone 13 
marrow spaces in OVX-induced osteoporotic rats, increased the proliferation and ALP activity 14 
and the expression of OPG of osteoblastic MG-63 cells, decreased the number of TRAP (+) 15 
multinucleated cells and the resorption areas of osteoclast from bone marrow cells (Oh et al., 16 
2003). The catalpol from fresh root of R. glutinosa has been reported to promote the 17 
proliferation and differentiation of osteoblasts of MC3T3-E1 cells (Wu et al., 2010). Acteoside, 18 
the main active compound of R. glutinosa, reduced OVX-induced bone loss and inflammatory 19 
cytokine production, inhibited osteoclast differentiation and maturation from bone marrow 20 
macrophages (BMMs) and RAW264.7 macrophages stimulated by the receptor activator of 21 
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nuclear factor-kappaB (NF-κB) ligand (RANKL) through suppressing RANKL-induced 1 
activation of mitogen-activated protein kinases and transcription factors such as NF-κ, c-Fos, 2 
and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), suggesting that acteoside may 3 
act as an anti-resorptive agent to reduce bone loss by blocking osteoclast activation (Lee et al., 4 
2013). 5 
5.4 Angelica sinensis (Oliv.) Diels (Root, Apiaceae) 6 
The root of Angelica sinensis (Oliv.) Diels. is one of the commonly used herbs in China, 7 
and is reported to possess hepatoprotective, neuroprotective, anti-oxidant, anti-osteoarthritis, 8 
and anti-cancer properties (Lim and Kim, 2014). The major active compounds of A. sinensis 9 
include phthalides, organic acids, polysaccharides and flavones (Chen et al., 2013). The 10 
extracts of root of A. sinensis significantly increased the bone femur mineral density, and 11 
decreased the markers of bone turnover in osteoporosis, serum ALP, collagen type I 12 
C-telopeptide and OCN of OVX rats, indicating that A. sinensis extract can prevent the 13 
OVX-induced bone loss in rats via estrogen-independent mechanism (Lim and Kim, 2014). 14 
Ferulic acid, a major active compound from A. sinensis significantly increased the BMD of 15 
tibia, slightly increased the serum levels of estrogen and progesterone and ALP activity, 16 
indicating that ferulic acid promotes bone remodeling, leading to a predominantly osteoblastic 17 
phase, besides bone resorption by osteoclasts (Sassa et al., 2003). 18 
5.5 Cornus officinalis Siebold & Zucc. (Fruit, Cornaceae) 19 
The fruit of Cornus officinalis Siebold & Zucc. is a folk medicine with a long history of 20 
safe use for the treatment of osteoporosis in postmenopausal women or elderly men in Asia. 21 
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The effects of cornus officinalis on RANKL-induced osteoclast differentiation from bone 1 
marrow-derived macrophages (BMMs) were evaluated by using RT-PCR and Western blot 2 
analysis. The results indicated that C. officinalis significantly inhibits RANKL-mediated 3 
osteoclast differentiation in a dose-dependent manner in bone marrow-derived macrophages, 4 
and inhibits the mRNA expression of TRAP, osteoclast-associated receptor, c-Fos, and nuclear 5 
factor of NFATc1 in BMMs, and protein expression of c-Fos and NFATc1, and greatly inhibits 6 
RANKL-induced phosphorylation of p38 and JNK, significantly suppresses RANKL-induced 7 
degradation of NF-κB (IκB), suggesting that C. officinalis may be useful in the treatment of 8 
osteoporosis (Kim et al., 2012). Sweroside is a bioactive ingredient isolated from C. officinalis, 9 
and it significantly increases the proliferation, activity of ALP and OCN, and attenuates and 10 
inhibits apoptosis of human MG-63 cells and primary osteoblasts from newborn rat calvaria 11 
(Sun et al., 2013). 12 
5.6 Astragalus membranaceus var. mongholicus (Bunge) P.K.Hsiao and A. membranaceus 13 
(Fisch.) Bunge (Root, Leguminosae)  14 
The dried root of Astragalus membranaceus var. mongholicus (Bunge) P.K.Hsiao and A. 15 
membranaceus (Fisch.) Bunge are known to contain cycloartane triterpene glycosides and 16 
flavonoids, particularly isoflavones, as its principal constituents. As a tonic used to strengthen 17 
muscles and bones, it is one of the most widely used medicinal herbs in Asian traditional 18 
medicine. The OVX rats administered extract from A. membranaceus showed a significant 19 
increase in Tb. Ar of the tibia, inhibited tibia and lumbar bone loss and did not cause uterine 20 
hypertrophy (Kim et al., 2003). A. membranaceus extract combined with supplemental Ca may 21 
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be more protective against the Ca loss of bone than A. membranaceus or supplementation of Ca 1 
alone in calcium-insufficient postmenopausal women (Kang et al., 2013). Supplementation 2 
with formononetin, the major compound of the A. membranaceus root resulted in slightly 3 
enhanced bone mechanical properties and bone density improvement, and prevented 4 
osteoporosis development in ovariectomized rats (Kaczmarczyk-Sedlak et al., 2013). The 5 
isoflavone calycosin-7-O-β-D-glucopyranoside (CG) is a principal constituent of A. 6 
membranaceus. Exposure of bone marrow stromal ST2 cells to CG in osteogenic 7 
differentiation medium increased ALP activity, OCN mRNA expression and the osteoblastic 8 
mineralization process, enhanced the expression of BMP- 2, p-Smad 1/5/8, β-catenin and 9 
Runx2, indicating that CG promotes the osteoblastic differentiation of ST2 cells through 10 
regulating the BMP/WNT signaling pathways. (Jian et al., 2015) 11 
5.7 Cinnamomum cassia (L.) J.Presl and Cinnamomum verum J. Pres (Bark, Lauraceae) 12 
Cinnamomum cassia (L.) J. Presl is one of the world’s oldest spices that has been used in 13 
foods, beverages and the cosmetic industry. In traditional oriental medicine, the bark of C. 14 
cassia has been used to improve various diseases caused by insufficient blood microcirculation, 15 
to treat gastritis, blood circulation disturbances and inﬂammatory disease. This medicinal plant 16 
has also been often administered to patients suffering from women’s diseases. The bark of C. 17 
cassia is reported to reduce blood pressure in experimental rats and possesses antiallergic, 18 
antiulcerogenic, antipyretic and anaesthetic activities. The ethanol extract from the bark of C. 19 
cassia signiﬁcantly induced the growth of MCF-7 cells, showed higher affinity with estrogen 20 
receptor (ER)-β compared with ERα, dose-dependently increased the cell survival, ALP 21 
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activity, collagen synthesis and OCN secretion in MC3T3-E1 cells, prevented apoptosis 1 
induced by TNF-α in osteoblastic cells. In the presence of TNF-α, the extracts inhibited the 2 
production of interleukin (IL)-6 and nitric oxide in osteoblastic MC3T3-E1 cells, suggesting 3 
that C. cassia has a direct stimulatory effect on bone formation in vitro and may contribute to 4 
the prevention of osteoporosis and inﬂammatory bone diseases (Lee and Choi, 2006). C. verum 5 
dose-dependently inhibited formation of osteoclast induced with RANKL from RAW 264.7 6 
cells without affecting cell viability and bone-resorbing activity of mature osteoclasts, inhibited 7 
RANKL-induced NFATc1 and c-fos expression, and moderately inhibited phosphorylation of 8 
IκB-α as evaluated by western blot, suggesting that C. verum inhibited bone resorption through 9 
regulating the c-fos/NFATc1 pathway rather than NF-κB pathway during RANKL-induced 10 
osteoclastogenesis. The cinnamaldehyde and 2-methoxycinnamaldehyde as active components 11 
reduced formation of osteoclast induced with RANKL from RAW 264.7 cells and inhibited 12 
NFATc1 expression whilst 2-methoxycinnamaldehyde exhibited remarkable inhibitory effects 13 
on bone resorption of osteoclast (Tsuji-Naito, 2008). 14 
5.8 Dipsacus asper Wall. (Root, Dipsacaceae) 15 
The dried root of Dipsacus asper Wall. is used for the treatment of traumatic ecchymoma and 16 
injury of muscles and bones by strengthening bone and curing bone fractures. It has also been 17 
used for treatment of back pain, traumatic hematoma, and bone fractures. Several chemical 18 
constituents, particularly saponins, iridoid glycosides and sterols, have been identified from D. 19 
asper. The crude extract of D. asper (DRE) is reported to increase bone density and alter bone 20 
histomorphology in mice (Wong et al., 2007). Treatment with D. asper extract is reported to 21 
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have a positive effect on mechanical strength, BMD, BMC, bone turnover markers, and 1 
significantly prevented the reduction of the bone volume fraction, connectivity density, 2 
trabecular number, thickness, tissue mineral density, and tissue mineral content as well as 3 
structure model index in ovariectomized rats through regulating the rate of bone remodeling, 4 
which could be inferred from the decreased level of bone turnover markers, such as serum ALP, 5 
OCN and urinary DPD (Liu, et al., 2009). DRE was demonstrated to prevent the loss of rat 6 
bone mass induced by hind limb unloading with vehicle treatment, which suggests the potential 7 
application of DRE in the treatment of microgravity-induced bone loss (Niu et al., 2015). Total 8 
saponins from D. asper enhanced the biomechanical strength of bone and attenuated the 9 
deterioration of trabecular bone microarchitecture in ovariectomized rats by decreasing levels 10 
of bone turnover markers. Total saponins from D. asper induced MC3T3-E1cells and primary 11 
osteoblastic cell maturation and differentiation, and increased bone formation by increasing 12 
BMP-2 synthesis, and inhibited osteoclastogenesis through an increase in osteoprotegrin and a 13 
decrease in RANKL expression in osteoblasts as detected by western blotting (Niu et al., 2012). 14 
5.9 Polygonium multiflora Thunb. (Root, Polygonaceae) 15 
Polygonium multiflora Thunb, which sometimes is named as Fallopia multiflora Thunb. 16 
has been widely used to treat age-related diseases. 2, 3, 5, 4’-tetrahydroxystilbene-2-O-β- 17 
D-glucoside, one of the major bioactive constituents extracted from P. multiﬂorum has been 18 
shown to have various pharmacologic activities such as antioxidant, increased cell survival, 19 
ALP activity, calcium deposition, and the mRNA expression of ALP, collagen I and OCN in 20 
osteoblastic MC3T3-E1 cells as measured by quantitative real-time PCR, and decreased 21 
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production of RANKL, IL-6 as evaluated by enzyme immunoassay system, intracellular 1 
reactive oxygen species and MDA of osteoblastic MC3T3-E1 cells injured by H2O2 as detected 2 
by assay kit, indicating that this compound may be effective in protection against osteoporosis 3 
associated with oxidative stress (Zhang et al., 2012a). 4 
5.10 Cuscuta chinensis Lam. and Cuscuta australis R.Br. (Seed, Convolvulaceae) 5 
The dry seed of Cuscuta chinensis Lam. and Cuscuta australis R.Br. is used as a tonic and 6 
aphrodisiac to nourish the liver and kidneys and to treat impotence and seminal emission, it is 7 
also widely used to improve sexual function, prevent and treat cardiovascular diseases, 8 
osteoporosis and senescence. Moreover, it possesses anti-tumoral, hepaprotective and 9 
neuropotective effects. The active constituents include ﬂavonoids, lignans, quinic acids and 10 
polysaccharides (Yang et al., 2011b). The aqueous extract of Cuscuta chinensis Lam. treatment 11 
mildly promoted the proliferation, ALP activity, collagen synthesis, mineralization and levels 12 
of BMP-2 in the MG-63 cells, suggesting that Cuscuta chinensis Lam. can play an important 13 
role in osteoblastic bone formation (Yang et al., 2009). ALP-guided fractionation led to the 14 
isolation of quercetin, kaempferol, isorhamnetin, hyperoside and astragalin from the crude 15 
ethanolic extract of Cuscuta chinensis Lam. Further study showed that kaempferol and 16 
hyperoside signiﬁcantly increased the ALP activity in UMR-106 cells, astragalin promoted the 17 
proliferation of UMR-106 cells. The isolated compounds showed estrogenic activity, but 18 
quercetin, kaempferol and isorhamnetin showed more potent ER agonist activity, 19 
demonstrating that kaempferol and hyperoside are the active compounds of Cuscuta chinensis 20 
Lam. demonstrating osteogenic effects (Yang et al., 2011b). 21 
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5.11 Cnidium monnieri (L.) Cuss. (Fruit, Apiaceae) 1 
The fruit of Cnidium monnieri (L.) Cuss. is used as a traditional remedy, and has been 2 
validated to possess a diverse set of pharmacological activities , including antiproliferative, 3 
vasorelaxant, antihepatitis, antimicrobacterial, anti-inflammatory, antiallergic functions and 4 
antiosteoporosis. The major active compounds of C. monnieri include essential oil, coumarines, 5 
chromones and triterpenoids. C. monnieri has been confirmed to be effective in the treatment of 6 
osteoporosis. Total coumarins can decrease bone loss in ovariectomized rats and in 7 
glucocorticoids induced osteoporosis rats. Total coumarins inhibited bone resorption of 8 
osteoclasts from bone marrow cells of neonatal rat, and increased rat calvaria osteoblast 9 
proliferation, differentiation and bone mineralized nodule formation (Qin et al., 2003).  10 
Osthole, the most important active compound from C. monnieri, can inhibit bone resorption by 11 
decreasing TRAP activity through RANKL/TRAF6/JNK signaling pathway in osteoclasts 12 
from long limb bones of new born rabbits as detected by quantitative real time PCR and 13 
Western blotting analysis, and obviously promoted the osteoblastic activity possibly through 14 
the regulation of Wnt/β-catenin signaling in the mice calvarial osteoblasts, promoted 15 
osteogenic differentiation through the BMP-2/p38MAPK/Runx2/osterix pathway as evidenced 16 
in quantitative real time PCR and Western blotting analysis (Ming et al., 2012;Tang et al., 17 
2010). Bergapten and imperatorin from C. monnieri also induced bone formation and promoted 18 
BMP-2 expression through the p38 and ERK-dependent signaling pathway in osteoblasts from 19 
calvaria of fetal rats as detected by quantitative real time PCR and Western blotting (Tang et al., 20 
2008). 21 
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6. Antiosteoporotic mechanisms of TCM formulas and their chemical constituents 1 
The research conducted over the years implies that the cause of osteoporosis is 2 
predominantly driven by the disorders of bone metabolism, of which the imbalance between 3 
bone formation and bone resorption play a major role. Bone formation, primarily mediated by 4 
osteoblasts, and resorption which is predominantly depended on the function of osteoclasts, is a 5 
balanced and continuous process. The activation of bone cells in bone remodeling process is 6 
regulated by multiple pathways that are fundamental in the development of therapy for 7 
osteoporosis, including the Wnt/β-catenin pathway, the PTH pathway, the BMP signaling 8 
pathway, the RANK/RANKL/OPG system and mitogen-activated protein kinase (MAPK) 9 
pathway. 10 
6.1 Antiosteoporotic mechanisms of TCM formulas 11 
6.1.1 Wnt/β-catenin pathway 12 
The Wnt/β-catenin pathway is known to be an important modulator of osteoblast function 13 
and bone formation. Wnt is the member of highly conserved secreted glycoprotein family, rich 14 
in cystein residue and is divided into two classes: canonical Wnts (wnt1, wnt3a) and 15 
non-canonical Wnts (wnt5a). This pathway is triggered by binding of canonical with frizzled 16 
(FZD) and LDL receptor related proteins (LRPs) which promote the phosphorylation and 17 
inactivation of glycogensynthase kinase 3 β (GSK3β) and prevents the degradation of β-catenin 18 
as well as subsequent translocation into the nucleus where it forms a complex with a T-cell 19 
factor to induce the transcription of osteoblastic genes (Lin and Hankenson., 2011). With the 20 
in-depth and numerous study of osteoporosis pathway, quite a few drugs have been found that 21 
they treat osteoporosis through the Wnt/β-catenin pathway. In primary osteoblast from 22 
neonatal rat calvaria, serum containing LW elicited significant increase in cell proliferation, 23 
alkaline phosphatase activity and amount of calcified nodules. The LRP-5, β-catenin, Runx2 24 
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and osterix, which are involved in the canonical Wnt/β-catenin signaling pathway, were 1 
significantly up-regulated in the presence of LW both in vivo and in vitro experiments as 2 
detected by real-time quantitative PCR, indicating that LW could alleviate osteoporosis through 3 
involving canonical Wnt/β-catenin signaling pathway (Xia et al., 2014). EZW increased the 4 
expression levels of wnt3α, LRP5 and β-catenin, and reduced the expression of dickkop of 5 
homolog 1 (DKK1) of alveolar bone in ovariectomized rats, suggesting that EZW may have 6 
potential anti-osteoporotic effects on osteoporotic alveolar bone by stimulating Wnt/β-catenin 7 
signaling pathway (Sun et al., 2014). 8 
6.1.2 MAPK pathway 9 
The MARK includes the extracellular signal-related kinases (ERKs), p38 and c-Jun 10 
N-terminal kinases, and contributes to cell morphogenesis, kinesis, apoptosis, proliferation, 11 
differentiation, growth and other physiological process (Chakraborty et al., 2016). It has been 12 
found that pharmacological serum of Bu Shen Ning Xin Decoction (BSNXD) enhanced the 13 
osteoblastic proliferation and inhibited the apoptosis of the osteoblasts from neonatal mouse 14 
calvaria through the activation of MARK signal transduction pathway via phosphoration of 15 
ERK as analyzed by Western blotting (Wang et al., 2009). Gu Ling Pian (GLP) can promote the 16 
proliferation and differentiation of MG-63 cells and regulate the ratio of OPG/RANKL via p38 17 
MARK pathway (Zhao et al., 2007). Si Wu Tang (SWT) extracts enhances ALP activity and 18 
bone mineralization, increase the expression of BMP-2 and OPN in MC3T3-E1 osteoblast cells 19 
by involving the regulation of phosphatidylinositol 3-kinase (PI3K), Akt and NF-κB signaling 20 
pathways as evaluated by quantitative real time PCR and Western blotting (Wu et al., 2013). 21 
6.2 Antiosteoporotic mechanisms of herbs and their chemical constituents 22 
6.2.1 BMP/SMAD signaling pathway 23 
BMP, which is pleiotropic cytokines belonging to the TGF-β superfamily, display 24 
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osteogenic properties. Runx2, as a transcription factor required for osteoblastogenesis. BMP 1 
binds heterodimeric receptors to activate Smad proteins, which transactivate osteoblastogenic 2 
genes either directly or via Runx2 (Lin and Hankenson, 2011). Recently, Icariin from 3 
Epimedium plant have been found to exert their potent osteogenic effect in pre-osteoblastic 4 
MC3T3-E1 cells and mouse primary osteoblasts through induction of Runx2 expression, 5 
production of BMP-4 and activation of BMP signaling as analyzed by Real-time RT-PCR 6 
analysis (Zhao et al., 2008). Maohuoside A induces SMAD4 expression in osteoblast from 7 
mouse bone marrow-derived mesenchymal stem cells as revealed by Real-time PCR and 8 
Western blot analysis (Cai et al., 2013). Total saponins from Dipsacus asper and Achyranthes 9 
bidentata increase bone formation by increasing BMP-2 synthesis in MC3T3-E1 and primary 10 
osteoblastic cells as analyzed using western blotting (Niu et al., 2012). Similarly, the aqueous 11 
extract of Cuscuta chinensis treatment mildly releases BMP-2, whilst markedly increasing 12 
mRNA expression of BMP-2 in the MG-63 osteoblastic cells (Yang et al., 2009).  13 
6.2.2 OPG/RANKL/RANK signaling pathway 14 
One of the most critical pathways in the osteoblast-osteoclast interaction scheme is the 15 
RANKL-OPG relationship. Receptor activator of NF-B (nuclear factor-κB) ligand is a key 16 
factor stimulating the differentiation and activation of osteoclasts, and therefore, is essential for 17 
bone remodeling (Suda et al., 1999). OPG is a soluble peptide originally described as a factor 18 
which markedly inhibits bone resorption and osteoclast differentiation in vitro (Rosen, 2000). 19 
Some herbs, including Epimedium brevicornu, Rehmannia glutinosa, Cornus officinalis have 20 
been demonstrated to be capable of inhibiting bone resorption, probably via pathways induced 21 
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by RANKL. RT-PCR were used to detect IL-6 and TNF-α expression, ELISA analysis was 1 
used to measure the levels of OPG and RANKL in osteoclast induced with lipopolysaccharide 2 
(LPS) in co-cultures of primary osteoblast and bone marrow cells. The results indicated that    3 
icariin from Epimedium brevicornu significantly inhibited LPS-induced osteoclastic bone 4 
resorption and IL-6, and TNF-α expression, up-regulated the gene expression of OPG and 5 
down-regulated RANKL in osteoclast (Hsieh et al., 2011). Ikarisoside A and icariin from 6 
Epimedium koreanum also showed inhibitory effects on osteoclastogenesis in 7 
RANKL-stimulated RAW 264.7 cells as well as in murine bone marrow-derived macrophages, 8 
and activation of NF-κB, JNK and Akt mediated by RANKL as analyzed by western blotting 9 
method (Choi et al., 2010). Similarly, acteoside, the main active compound of Rehmannia 10 
glutinosa, inhibited differentiation and formation of osteoclast from bone marrow macrophages 11 
(BMMs) and RAW264.7 macrophages stimulated by RANKL, attenuated RANKL-stimulated 12 
activation of p38 kinase, ERK, and JNK, and transcription factors such as NF-κB, c-Fos and 13 
NFATc1 as analyzed by electrophoretic mobility shift assay and RT-PCR analysis (Lee et al., 14 
2013). Cornus officinalis significantly inhibits RANKL-mediated osteoclast formation and 15 
differentiation from bone marrow-derived macrophages (BMMs) through inhibiting the 16 
protein expression of c-Fos and NFATc1, RANKL-induced phosphorylation of p38 and JNK, 17 
and degradation of I-κB in BMMs as measured by western blotting. (Kim et al., 2012). 18 
6.2.3 MAPK signaling pathway 19 
The mitogen-activated protein kinases, the family of secondary messengers that convey 20 
signals from the cell surface to the nucleus (Yang et al., 2013), play important roles in cellular 21 
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response to growth factors, cytokines, or environmental stress. There are three major families of 1 
MAPKs, ERK, which is involved in cell proliferation/transformation and survival, c-Jun 2 
N-terminal kinase is involved in stress responses and p38 MAPKs is involved in many cellular 3 
processes (Kim et al., 2013a). Some herbs have been demonstrated to have an effect on 4 
osteoporosis via MAPK pathway. Icariin suppresses LPS-induced osteoclastogenesis program 5 
and osteoclastic bone resorption, inhibits LPS-mediated activation of the p38 and JNK of 6 
osteoclast in co-culture of primary osteoblast and bone marrow cells as measured by western 7 
blotting, indicating that icariin has an in vitro inhibitory effect on osteoclasts differentiation 8 
through p38 and JNK pathway (Hsieh et al., 2011). Achyranthes bidentata saponins were 9 
effective in preventing and treating retinoic acid-induced osteoporosis. RT-PCR and 10 
Western-blotting analysis showed that Achyranthes bidentata saponins induce proliferation 11 
and differentiation of osteoblast from bone marrow stromal cells (BMSCs), increase mRNA 12 
levels of BMP-2, runt-related transcription factor 2 and osterix via activation of the ERK 13 
signaling pathway (He et al., 2014). 14 
7 Comparison between the efficacy of TCM formulas and the efficacy of single herbs 15 
Epimedium plants are commonly used antiosteoporotic botanical medicine, and used in 16 
most of antiosteoporotic TCM formulas. The antiosteoporotic chemical constituents in 17 
Epimedium plant are flavonoids. Therefore, the flavonoids were extracted and purified from 18 
Epimedium plant to observe their antiosteoporotic activity on primary osteoporosis, and Gu 19 
Song Bao Jiao Nang was used as control. The content of flavonoids in Epimedium extracts 20 
were more than 50%, 360 patients were given 0.7g Epimedium extract/time, three times / day 21 
for 24weeks. Epimedium plant is major component of Gu Song Bao Jiao Nang, and occupies 22 
  33 
58% in this formula. 120 patients were given 1g Gu Song Bao Jiao Nang/time, three times / 1 
day for 24 weeks. The results demonstrated that Epimedium extracts can more effectively 2 
improve BMD of patients than Gu Song Bao, but effects of Epimedium extracts in relieving 3 
pain are weaker, and the incidence of adverse effect of Epimedium extracts (6.67%) are higher 4 
than that of Gu Song Bao (5%). Therefore, TCM formulations showed significant advantage 5 
in integral regulation of bone metabolism and reduction in adverse effects (Lu et al., 2013).   6 
     EXD is composed of six herbal medicines, with Epimedium herbs being its major 7 
ingredient. Epimedium herb occupies 20% in EXD. The content of flavonoids and icariin were 8 
respectively as 5.0% and 1.7% in Epimedium herb. The content of flavonoids in Epimedium 9 
extract is 60%. At the dose of 6g/kg EXD, 100mg/Epimedium extracts, 20mg/kg icariin and 10 
1mg/kg nylstriol, we compared their potentials on osteoporotic bone and reproductive tissues 11 
in ovariectomized rats. The results showed that EXD has more potential effects in increasing 12 
BMD and regulating bone histomorphometric parmeters and biochemical parameters in OVX 13 
rats, EXD is similar to estrogen and exerts a concomitant effect on bone formation and bone 14 
resorption at the tissue level, while Epimedium extracts and icariin produced bone-protective 15 
effects mainly by inhibiting bone resorption. Nevertheless, EXD, Epimedium extracts, and 16 
icariin treatments manifested a fewer adverse effects on the uterus, mammary gland, and 17 
vagina compared to estrogen administrations. Among the EXD, Epimedium extracts, and 18 
icariin, EXD was found to have superior efficacy and safety profile (Xue et al., 2012). 19 
8. Conclusion  20 
TCM formulas not only reduce bone loss by decreasing bone resorption and increasing 21 
bone formation through multi-component and multi-targets, but also regulate the body’s 22 
function in overall and relieve the pain in back and lumbago. The herbal medicine that possess 23 
activity of replenishing kidney are often shown to have estrogen-like, antioxidant activity or 24 
regulating the function of hypothalamus-pituitary axis to enhance the estrogen level in serum, 25 
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and the herbal medicine that reinforce spleen can intensify the effects of tonifying kidney, and 1 
herbal medicine activating blood can help active chemical constituents to arrive at the skeleton 2 
site and regulate bone metabolism. Furthermore, TCM formulas modulate bone metabolism 3 
networks modestly and then alleviate symptom of osteoporosis at low concentration through 4 
exerting synergistic effects of multiple component. Therefore, rationally designed TCM 5 
formula also can be considered as an option for multitarget therapeutic and prophylactic 6 
applications. Development of standardized, synergistic, safe and effective TCM formula with 7 
robust scientiﬁc evidence can offer faster and more economical alternatives.  8 
Aging, estrogen deficiency, chemical drugs, and decreased mechanical loading may cause 9 
bone loss leading to osteoporosis. The corresponding animal models are respectively castrated 10 
osteoporotic models, osteoporotic models caused by drugs and disused osteoporotic models. 11 
The investigations of TCM formulas on osteoporotic animals focus on osteoporotic rats 12 
induced by ovariectomy, glucocoroticoids and retinoic acid, and lack other osteoporotic animal, 13 
such as disuse model. The determined parameters in animal experiments did not reflect the 14 
action characteristic of TCM formulas. Therefore, some novel TCM formulas should be 15 
developed and studied in animal models, such as disuse osteoporotic rats, some specific 16 
parameters that are associated with animal model should be analyzed to highlight the 17 
antiosteoporotic characteristic of TCM formulas. 18 
Antiosteoporotic effects of TCM formulas are attributed to active chemical constituents of 19 
their herbs. These active constituents are diverse in chemical structure, including flavonoids, 20 
saponin, lignans and coumarins, and have the potential to be developed as antiosteoporotic 21 
leads. Hence, phytochemicals from TCM formulas and the composition of their herbs is of 22 
great potentials for the development of novel antiosteoporotic drugs. There is some 23 
accumulated evidence of the value of TCM in the treatment of osteoporosis. EXD, a TCM 24 
formula is composed of Curculigo orchioides Gaertn. (Rhizome, Hypoxidaceae), Epimedium 25 
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plant (Leaf, Berberidaceae), Phellodendron chinense C.K.Schneid (Bark, Rutaceae), Morinda 1 
officinalis F.C.How (Root, Rubiaceae), Angelica sinensis (Oliv.) Diels (Root, Apiaceae), 2 
Anemarrhena asphodeloides Bunge (Rhizome, Liliaceae). By investigating the 3 
antiosteoporotic chemical constituents and their interaction relationship, we found that icariin 4 
and icaritin from Epimedium leaf has estrogen-like activity and regulatory effects on bone 5 
metabolism; curculigoside from rhizome of Curculigo orchioides Gaertn. is an antioxidant and 6 
protective agent for injured osteoblast; berberine from bark of Phellodendron chinense is 7 
inhibitor for bone resorption; Timosaponin from rhizome of Anemarrhena asphodeloides and 8 
ferulic acid from root of Angelica sinensis, respectively are bone anabolic agent. In addition, 9 
root of Morinda officinalis contains iridoid glycoside and anthraquinone, which have been 10 
shown to have anti-inflammation and inhibitory effects on bone resorption (Chen et al., 2008). 11 
Taken together, antiosteoporotic TCM formula indeed contains various antiosteoporotic 12 
components, which are likely to act synergistically to decrease bone loss. Thus, combining 13 
these antiosteoporotic chemical constituents (or candidates) in TCM formula may exhibit better 14 
antiosteoporotic effects than the single compounds; this will provide a good starting point for 15 
further research. 16 
Compared with chemical drugs, TCM formulas have the advantage of fewer side effects, 17 
are relatively cheap, and suitable for long-term use. A mass of clinical practice and animal 18 
experiment shows that TCM formulas can not only repair bone microarchitecture, increase 19 
bone mass, improve bone biomechanical properties, but also can reduce or eliminate the 20 
lumbar debility, back pain and other symptoms (Yang et al., 2011a; Zhu et al., 2012a). The 21 
single herb medicine that exists in TCM formulas for therapy of osteoporosis often contains 22 
antiosteoporotic compounds, thus screening active compounds from TCM formulas and 23 
determining the composition of the herbal medicine will help to find antiosteoporotic leads or 24 
candidates. The chemical compounds in TCM formulas produce synergistic effects; this may 25 
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lead to the discovery of antiosteoporotic chemical compounds which can be used in 1 
combination. Therefore, systematic data mining of the existing antiosteoporotic TCM 2 
formulas database can certainly help the drug discovery processes to identify safe candidates 3 
and synergistic formulations. 4 
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